EIGR Investors Have Opportunity to Lead Eiger BioPharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES, Dec. 2, 2022 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ: EIGR). Class Period:…